Revance's RT002 misses in Phase IIa for plantar fasciitis

Revance Therapeutics Inc. (NASDAQ:RVNC) said DaxibotulinumtoxinA for Injection (RT002) missed the primary endpoint of reducing patient-reported foot pain as measured by visual analog scale (VAS) score from baseline to week eight vs. placebo in a Phase IIa trial to treat plantar fasciitis.

Interim data showed a single injection of 240 units of RT002 reduced mean VAS score from baseline to week eight by 54.2% vs. 42.6% for placebo (p=0.39). Revance said the result was driven “by a strong placebo response in the control group at two of the five study sites.”...